Supplementary Figure 1 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Abstract

Pathways targeted by the Dana-Farber Targeted Therapy Collection and clinical development status</p